Related Experiment Videos
[Methotrexate resistance in acute leukemias].
1Katedra i Klinika Pediatrii, Hematologii i Onkologii Akademii Medycznej w Bydgoszczy.
Summary
Cellular resistance to methotrexate can cause treatment failure in acute lymphoblastic leukemia. Strategies like continuous infusion or new antifolates can overcome methotrexate resistance, improving therapy outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Context:
- Methotrexate is a crucial cytostatic agent for acute lymphoblastic leukemia (ALL).
- Cellular resistance to methotrexate frequently leads to therapeutic failure.
- Understanding resistance mechanisms is vital for optimizing ALL treatment.
Purpose:
- To review the mechanisms of cellular resistance to methotrexate in acute lymphoblastic leukemia.
- To explore strategies for circumventing methotrexate resistance in ALL and other leukemias.
- To identify novel antifolate agents with potential to overcome existing resistance pathways.
Summary:
- Key resistance mechanisms include reduced drug uptake/retention, impaired polyglutamylation, altered target enzymes (DHFR), and apoptosis evasion.
- Continuous methotrexate infusion shows promise in overcoming resistance in T-ALL, relapsed ALL, and AML.
- Novel antifolates designed to bypass transport limitations, independent of polyglutamylation, and with enhanced target affinity offer alternative therapeutic approaches.
Impact:
- This review highlights potential therapeutic strategies to improve treatment efficacy in methotrexate-resistant leukemias.
- It provides insights for the development of next-generation antifolate drugs.
- Optimizing methotrexate delivery and exploring new drug candidates can enhance patient outcomes in leukemia therapy.